[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/pages/docs/Benef/index.md) >> Individual ID:PBN__Benef_589 

# __Antiviral targets__

## Articles mentionning this Benefit

* [Current knowledge of COVID-19: Advances, challenges and future perspectives](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_118.md)

## Category to which it belongs

* [Enhanced measures to inhibit the dissemination and transmission of viruses, including reducing concentration and spread.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_10.md)

## Description of actual returns pertaining to this benefit

* [Potential for new drug development and intellectual property](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_644.md)

## Name of the Benefit

Identification of additional receptors for intervention

## Risks which can benefit from this action

* [Proteolysis of s protein by cathepsin](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_593.md)

## Stakeholders benefitting from this Benefit

* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)

